DNER and breast neoplasm: However, the CDK4/6 inhibitor Palbociclib, similar to that of BET inhibitor, achieved a synergistic effect with AKTi in suppressing breast tumor cell growth, suggesting that the kinase activity of CDK6 is important for the intrinsic resistance to AKTi.